Skip to main content
. 2019 Oct 22;11(10):1613. doi: 10.3390/cancers11101613

Figure 6.

Figure 6

MIR452 inhibited CRC cell growth and angiogenesis in the xenograft model. (A) MIR452 inhibited CRC cell growth in vivo. An image of xenograft tumors derived from HT29 cells transfected with the MIR452 mimic or mock control (upper panel), and the siVEGFA or mock control (bottom panel). (B) Volumes of the xenograft tumors derived from HT29 cells transfected with the MIR452 mimic, siVEGFA, or mock controls in nude mice. (n = 8, mean ± SD). Three independent experiments were performed using 2–3 mice per experiment. (C) Expression of the cell proliferation marker MKI67 (the top column), VEGFA (the second column from the top), VEGFR2 (the third column from the top), and endothelial cell marker CD31 (the fourth column from the top) in the xenograft tumors formed after subcutaneous transplantation of HT29 cells transfected with the MIR452 mimic, siVEGFA, or mock controls (200× magnification). Three independent experiments were performed in duplicate, and the p-values were calculated by using Student’s t-test (* p < 0.05).